120807-29-6

Basic information

• Product Name: 1-[4-(trifluoromethyl)phenyl]piperidin-4-one
• Synonyms: 1-[4-(trifluoromethyl)phenyl]piperidin-4-one;1-[4-(Trifluoromethyl)phenyl]-4-piperidinone
• CAS NO: 120807-29-6
• Molecular Formula: C₁₂H₁₂F₃NO
• Molecular Weight: 243.2249896
• Mol File: 120807-29-6.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-[4-(trifluoromethyl)phenyl]piperidin-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[4-(trifluoromethyl)phenyl]piperidin-4-one(120807-29-6)
• EPA Substance Registry System: 1-[4-(trifluoromethyl)phenyl]piperidin-4-one(120807-29-6)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 120807-29-6(Hazardous Substances Data)

Usage

Structure

Piperidinone derivative with a trifluoromethyl group attached to the phenyl ring

Industry use

Pharmaceutical industry as a building block for the synthesis of various biologically active compounds, including drugs and agrochemicals

Potential applications

Intermediate in the development of new pharmaceuticals and agrochemicals, ligand in organometallic chemistry, reagent for the functionalization of organic molecules

Unique chemical properties

The presence of the trifluoromethyl group and the piperidinone structure contribute to its unique properties and potential applications in various fields.

Upstream product

• 402-43-7 p-trifluoromethylphenyl bromide 
• 177-11-7 4,4-ethylenedioxy-piperidine 
• 681508-70-3 4-hydroxy-[4-(trifluoromethyl)phenyl]piperidine 
• 402-44-8 4-Fluorobenzotrifluoride 
• 584-08-7 potassium carbonate 

Downstream Products

• 948022-55-7 C₁₆H₁₈F₃NO₂ 
• 948022-65-9 C₁₈H₂₂F₃NO₂ 
• 948022-60-4 C₁₈H₂₂F₃NO₄ 

Relevant articles and documents

Synthesis, biological evaluation and molecular modeling of a novel series of fused 1,2,3-triazoles as potential anti-coronavirus agents

Synthesis and biological evaluation of a novel library of fused 1,2,3-triazole derivatives are described. The in-house developed multicomponent reaction based on commercially available starting materials was applied and broad biological screening against various viruses was performed, showing promising antiviral properties for compounds 14d, 14n, 14q, 18f and 18i against human coronavirus 229E. Further in silico studies identified the key molecular interactions between those compounds and the 3-chymotrypsin-like protease, which is essential to the intracellular replication of the virus, supporting the hypothesis that the protease is the target molecule of the potential antiviral derivatives.

NIROGENOUS HETEROCYCLIC DERIVATIVES SUBSTITUTED WITH CYCLIC GROUPS

It was found out that the nitrogen-containing heterocyclic derivative represented by the formula (I) specifically binds to a receptor of NR1/NR2B, and is used as a NR2B receptor antagonist. A compound represented by: wherein Z is N or CR1, A1 is a nitrogen-containing aromatic monocyclic group which is optionally substituted, a nitrogen-containing aromatic fused cyclic group which is optionally substituted etc., A2 is an aromatic hydrocarbon cyclic group or an aromatic heterocyclic group, each optionally having a substituent, R1, R2, Ra, Rb, Rc and Rd are each independently hydrogen, hydroxy, etc., w is 2 or 3, t is 1 or 2, X is -(CR3R4)m-, -CO(CR3R4)n-, -CONR5(CR3R4)n- etc., m is an integer of 1 to 4, n is an integer of 0 to 4, R3 and R4 are each independently hydrogen, halogen, hydroxy etc., and R5 is hydrogen or lower alkyl, or a pharmaceutically acceptable salt, or a solvate thereof.

An improved synthesis of N-aryl and N-heteroaryl substituted piperidones

An efficient Pd(0)-catalyzed protocol for the rapid and efficient preparation of N-aryl and N-heteroaryl substituted piperidones is described. The two step syntheses proceed with an overall yield of 50-70% using X-Phos as optimal ligand for the Pd(0)-cata

2-Arylbenzo(b)(1,6)naphthyridines as inhibitors of interleukin 1

There is disclosed a method for the treatment of inflammatory conditions and of collegenase-induced tissue destruction which comprises the administration of a therapeutically effective amount of a compound of the formula STR1 wherein R1 is phen